Business Context and Reporting Period
This Form 8-K Current Report, dated April 27, 2026, covers Intellia Therapeutics, Inc.'s entry into a material definitive agreement for a public offering of common stock. The report also provides preliminary unaudited financial data as of March 31, 2026, prior to the completion of the quarter-end financial close.
Key Financial Metrics
- Public Offering Proceeds: The Company sold 16,744,187 shares at $10.75 per share. Underwriters exercised the full 30-day option to purchase an additional 2,511,628 shares. Estimated net proceeds were approximately $194.6 million after underwriting discounts and expenses.
- Liquidity Position: As of March 31, 2026, preliminary unaudited cash, cash equivalents, and marketable securities totaled approximately $517.2 million.
- Recent Equity Activity: The Company raised approximately $33.6 million in net proceeds from an "at the market" equity offering program during the quarter ended March 31, 2026.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or margin figures for the period.
- Debt: The filing text does not provide specific debt figures.
Material Changes and Outlook
The primary material change is the significant increase in liquidity resulting from the completed public offering. Management intends to use the net proceeds to advance clinical development, prepare for the commercial launch of lead programs, research pipeline candidates, pursue potential acquisitions, and fund working capital.
Cash Runway: Management believes the net proceeds, combined with existing cash and collaboration funding, will fund operating expenses and capital expenditures at least into 2028. This projection excludes potential revenue from the anticipated approval of lonvoguran ziclumeran for hereditary angioedema in the first half of 2027, as well as potential milestone payments or extension fees.
Risks and Contingencies
- Forward-Looking Statements: Projections regarding cash runway, product approval timelines, and use of proceeds are subject to risks and uncertainties that may cause actual results to differ materially.
- Preliminary Data: The financial data disclosed (cash position as of March 31, 2026) is preliminary, unaudited, and subject to change upon completion of the financial statement closing procedures.
- Regulatory Approval: The cash runway estimate relies on the assumption of no product sales revenue prior to the potential approval of lonvoguran ziclumeran in H1 2027.
Investor Verification Checklist
- Verify the final audited cash, cash equivalents, and marketable securities balance for the quarter ended March 31, 2026, once the financial close is complete.
- Confirm the final net proceeds from the public offering after all offering expenses are settled.
- Monitor the regulatory status and approval timeline for lonvoguran ziclumeran for hereditary angioedema, as this impacts the revenue assumptions in the cash runway projection.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and indemnification terms.